Press Releases

 
Press Releases
Date Title and Summary View
Dec 12, 2017 SALT LAKE CITY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Dec 8, 2017 SALT LAKE CITY, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Dec 6, 2017 SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Nov 10, 2017 SALT LAKE CITY, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the Department of Veterans Affairs (VA) recently initiated a national, multi-center trial to evaluate the company's GeneSight® test to help improve health outcom...
Nov 9, 2017 SALT LAKE CITY, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the Jefferies Healthcare Conference at 8:40 a.m. GMT on November 16, 2017, at the Waldorf Hilt...
Nov 7, 2017 Total Revenues of $190.2 Million Up 7 PercentGAAP Diluted EPS of $1.15 and Adjusted EPS of $0.26 Up 13 PercentGeneSight® Demonstrates Statistical Significance for Response and Remission in Prospective Study SALT LAKE CITY, Nov. 07, 20...
Nov 6, 2017 BALTIMORE and SALT LAKE CITY, Nov. 06, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular diagnostics and personalized medicine, today announced that they have signed an agreement to collaborate on a clinical utility study for the Vectra® D...
Nov 2, 2017 SALT LAKE CITY, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced positive results from a double-blind, multi-center, randomized controlled trial assessing the impact of the GeneSight® Psychotropic test (GeneSight) on psychiatric tr...
Oct 30, 2017 SALT LAKE CITY, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 3-8, 2017 in San Diego, Calif.  Vectra DA has been show...
Oct 26, 2017 SALT LAKE CITY, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Page:
1
... NextLast
= add release to Briefcase